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Abstract
The Toxicology Investigators Consortium (ToxIC) Registry was established by the American College of Medical Toxicology in
2010. The registry collects data from participating sites with the agreement that all bedside and telehealth medical toxicology
consultation will be entered. This eleventh annual report summarizes the Registry’s 2020 data and activity with its additional
6668 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from January 1
to December 31, 2020. Detailed data was collected from these cases and aggregated to provide information which included
demographics, reason for medical toxicology evaluation, agent and agent class, clinical signs and symptoms, treatments and
antidotes administered, mortality, and whether life support was withdrawn. Gender distribution included 50.6% cases in females,
48.4% in males, and 1.0% identifying as transgender. Non-opioid analgesics were the most commonly reported agent class,
followed by opioid and antidepressant classes. Acetaminophen was once again the most common agent reported. There were 80
fatalities, comprising 1.2% of all registry cases. Major trends in demographics and exposure characteristics remained similar to
past years’ reports. Sub-analyses were conducted to describe race and ethnicity demographics and exposures in the registry,
telemedicine encounters, and cases related to the COVID-19 pandemic.
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Introduction
The year 2020 marked the beginning of the second decade of
the Toxicology Investigators Consortium (ToxIC). It was a
year marked by considerable expansion of ToxIC’s activities.
Our case accrual unabatedly continued, and we welcomed six
new sites to the consortium.
Starting in 2020 ToxIC began a partnership with the US
Centers for Disease Control and Prevention (CDC) Overdose
Data to Action (OD2A) program. Through a data sharing
agreement, ToxIC is working with our partners at OD2A to
provide data on our experience with opioid and psychoactive
substance toxicity. Given the uniqueness of our physician led
data collection, ToxIC’s patient-oriented database is
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supplying a level of detail on adverse drug effects not gener-
ally available from alternate drug-toxicity databases. As our
partnership with the CDC grows, we expect to collaborate
with their overdose prevention efforts through our main
Core Registry, our pediatric opioid and marijuana
Sub-Registries, and our novel efforts on opioid and stimulant
exposures.
In 2020 ToxIC embarked on two prospective multicenter
projects in addition to the continuation of its Core Registry.
These two projects are not based on bedside medical toxicol-
ogy consultations and utilize their own unique data collection
interface.
The first multicenter project started its initial year of a
5-year NIH-supported prospective clinical study of opioid
overdoses presenting to the emergency department (NIH#
1RO1DA037317- 02). Alex Manini, MD, Professor of
Emergency Medicine at the Mt Sinai Icahn School of
Medicine and a long time ToxIC collaborator, is the
Principal Investigator of this project which characterizes the
clinical course, patient characteristics, and in-depth toxicolog-
ic analysis of fentanyl analogs (or “fentalogs”). In the course
of the Fentalog project, ToxIC is assessing the prevalence and
role of fentalogs, novel psychoactive drugs, adulterants, and
other substances in the clinical presentation and treatment of
these patients. In a supplement to this grant, ToxIC is also
partnering Mt Sinai on data collection specific to factors relat-
ed to COVID-19 infections in patients with a history of opioid
misuse. This is the first ToxIC project that has included com-
prehensive toxicological testing, utilizing liquid chromatogra-
phy quadrupole time-of-flight mass spectrometry to elucidate
the presence of psychoactive substances and their metabolites.
In 2020, the COVID-19 pandemic significantly altered hu-
man activity in a multitude of ways. The medical and public
health communities vibrantly came to life in a way that had
not been seen in a century. As these communities rose to the
challenge and aggressively took action to deal with the evolv-
ing pandemic, ToxIC quickly mobilized. As we continued our
data sharing agreement adopted in 2016 with the US Food and
Drug Administration (FDA), new therapeutics were rapidly
entering clinical practice via Emergency Use Authorizations
employed in a time of unprecedented need. Simultaneously,
measures taken by the lay community to prevent and combat
COVID-19, such as taking hydroxychloroquine and drinking
bleach, reached a concerning level. Because of our already
existing data sharing agreement with the FDA and the need
to expeditiously identify adverse drug events in this rapidly
evolving environment, ToxIC and the FDA collaboratively
implemented a real-time national toxicosurveillance project
searching for adverse drug events associated with COVID-
19 prophylaxis or treatment. The so-called FDA ACMT
COVID-19 ToxIC (FACT) Pharmacovigilance Project was
organized and swiftly pressed into action. Similar to the
Fentalog project above, the FACT project is not based on
the ToxIC Core Registry or bedside medical toxicology con-
sults, and data is collected through a separate mechanism and
database.
In addition to the summary Core Registry data, this year we
are presenting additional data on the use of telemedicine by
medical toxicologists, as well as taking a closer look at race
and ethnicity, and COVID-19 positive cases since the start of
the pandemic.
Twelve full ToxIC publications in six separate journals
were published in 2020. This is the largest number of journal
publications in any year since ToxIC’s inception. Sixteen
ToxIC abstracts were published from both national and inter-
national meetings. These full publications and abstracts are
enumerated on the ToxIC website: www.ToxICRegistry.org.
In addition to the above, the following new ToxIC research
projects were proposed and initiated by ToxIC investigators in
2020:
1. Effect of activated charcoal administration on clinical
outcome
2. A comparison of clinical outcomes following benzodi-
azepine or Z-drug toxicity
3. A comparison of hydroxyzine and diphenhydramine
poisonings
4. The effect or race and ethnicity on access to opioid treat-
ment facilities
5. Organ donation after death from a toxic exposure
6. Fomepizole use in acetaminophen poisoning
7. Epidemiology of pediatric antiepileptic drug poisoning
8. Trends in gastrointestinal decontamination after acute
poisoning
9. Trends in toxicity from household cleaners and sanitiz-
ing agents
10. Toxicity of chloroquine and hydroxychloroquine
In 2020 ToxIC was supported by the NIH, FDA, CDC, and
BTG International. These collaborations have been enriching
for ToxIC but more importantly have provided unique net-
working opportunities for ToxIC investigators.
Methods
ToxIC was started on January 1, 2010, as a Case Registry [1].
That Core Registry continues today and prospectively enrolls
patients presenting to participating sites. All sites agree to
enter all inpatients or outpatients presenting to their site on
whom a formal medical toxicology consultation was complet-
ed. ToxIC staff periodically meet with all sites to review pa-
tient accrual, obstacles to achieving full compliance with pa-
tient entry, quality assurance efforts, and ongoing project op-
portunities. Deidentified case information is entered into an
online data collection form using the REDCap (Research
J. Med. Toxicol.
Electronic Data Capture) platform. REDCap is a secure,
web-based software platform designed as an electronic data
capture tool for research studies hosted at the Vanderbilt
University Health Core. REDCap provides (1) an intuitive
interface for validated data capture, (2) trail audits for tracking
data manipulation and export procedures, (3) automated ex-
port procedures for seamless data downloads to common sta-
tistical packages, and (4) procedures for data integration and
interoperability with external sources.
In 2020, the Core Registry collected data in the following
areas:
1. Names, sites, and specific facility of the enteringmedical
toxicologist(s)
2. Specific focused data collections on areas of contempo-
rary interest




6. Specific aspects of the patient’s medical history
7. The source of the patient referral
8. The reasons for the patient requiring a medical toxicol-
ogy consultation
9. The implicated substance(s) and their relationship, if
any, to the patient’s presentation
10. Patient signs and symptoms
11. Specific laboratory and electrocardiographic data
12. Treatments administered
13. Outcome
ToxIC’s data collection in 2020 included the addition of
teletoxicology and COVID-19 status (defined as a positive
SARS-CoV-2 test). A full enumeration of all fields collected
in the Core Registry is provided in the supplemental materials.
In addition to the Core Registry data collected on every
bedside medical toxicology consultation, there are five de-
tailed Sub-Registries that are completed on relevant patients.
These are:
1. North American Snakebite Registry
2. Pediatric Marijuana and Opioid Registry
3. Extracorporeal Therapies Registry
4. Lipid Emulsion Therapy Registry
5. Natural Toxins Registry: Mushrooms and Plants
ToxIC has been reviewed by the Western Institutional
Review Board (IRB) and operates in pursuant to the approval
of the participating site IRBs. All data collected by ToxIC is
deidentified and is compliant with the Health Insurance
Portability and Accountability Act. All cases entered into the
Core Registry, Sub-Registries, FACT Pharmacovigilance
Project, and the Fentalog project are reviewed for quality
assurance by the ToxIC staff. Any inconsistent or incomplete
entries are queried back to the entering medical toxicologist
for correction or clarification.
Additional information regarding ToxIC can be found at
https://www.toxicregistry.org.
Results
In 2020 there were a total of 6668 individual cases of toxico-
logic exposures reported to the ToxIC Registry from 37 sites
comprised of 58 separate health care facilities. This is a de-
crease in total cases compared with 2019 [2]. Individual facil-
ities contributing cases in 2020 are listed in Table 1.
Demographics
Tables 2 and 3 summarize selective demographics for age and
gender and race and ethnicity, respectively. Gender break-
down was similar to recent years [2–5]. In 2020, 50.6% of
cases involved female patients, and 1% involved transgender
or gender non-conforming patients (37 female-to-male, 17
male-to-female, 8 gender non-conforming). Sixty-nine pa-
tients (1%) were pregnant. Age distribution was similar to
recent years. Adults age 19–65 made up approximately half
of the cases (55.5%) followed by adolescents age 13–18
(24.6%). Children (< 12 years of age) made up 9.5%; 5.9%
of cases involved older adults (> 65 years of age).
The most commonly reported race was Caucasian (62.6%),
followed by Black/African (15.1%) and Asian (2.3%).
Hispanic ethnicity was reported in 12.4% of cases; however
15.7% of cases reported ethnicity as unknown/uncertain. Race
and ethnicity are self-reported by patients, or in cases in which
a patient is unable to report, it may be determined by the
examining medical toxicologist to the best of their ability or
abstracted from the medical record.
Table 4 details the referral source of inpatient and outpa-
tient medical toxicology encounters. The majority (53.5%) of
inpatient cases were generated by the emergency department,
and very few cases were referred from poison centers (0.2%)
or outpatient physicians (0.2%). Outpatient encounters were
primarily referred by primary care and other outpatient physi-
cians (68.7%), followed by self-referrals (11.0%). These
trends were similar to recent years.
Tables 5 and 6 describe the reason for the toxicology en-
counter and the details of intentional pharmaceutical expo-
sures, respectively. Consistent with recent years, intentional
pharmaceutical exposures were by far the most common rea-
son for medical toxicology encounters (43.8%). Addiction
medicine consult was a new reason for encounter in 2018
and has increased in frequency each year (2.7% to 6.6% to













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the majority of cases were again an attempt at self-harm
(73.9%), primarily suicide attempts (87.5%).
Tables 7 and 8 describe the top three primary reasons for
encounter by race and ethnicity, respectively. Distribution of
reasons for encounter was largely similar across races and
ethnicities, with intentional pharmaceutical exposures being
the most common reason for encounter across all groups. Of
note, however snake envenomation was a top three encounter
reason among Native American/Alaska Native (8.2%) and
Asian (17.4%) race groups, but not among other race groups.
Addiction medicine consultation was the primary reason for
the encounter in 5.9% of non-Hispanic patients, but only 3.4%
of Hispanic patients.
Agent classes
Agent class contributions to the Core Registry are described in
Table 9. In 2020, of the 6668 cases entered into the ToxIC
Registry, 5987 included specific agents of exposure. Four
thousand two hundred sixty-two (71.2%) cases involved sin-
gle agents. Consistent with recent years, the non-opioid anal-
gesic class was the most common (15.5%) class of drugs
reported. Again in 2020, the opioid class was the second most
common agent class reported (12.7%) [2] followed by the
antidepressant (10.4%) and ethanol (8.4%) classes.
Tables 10 and 11 detail the top five agent classes broken
down by race and ethnicity, respectively. The primary sub-
stance responsible for most encounters varied across racial
groups: ethanol for Native Americans/Alaska Natives
(13.7%); analgesics for Asians (10.3%), Caucasians
(14.4%), and mixed-race patients (21.1%); opioids for
Blacks (17.0%); and toxic alcohols for Pacific Islanders/
Native Hawaiians (28.6%). Primary substances associated
with both Hispanic and non-Hispanic patient encounters were
similar.
Analgesics
Table 12 presents the non-opioid analgesics, the largest class
in the Core Registry. Acetaminophen was again the most
commonly reported agent (64.6%), reaching its claim as the
highest reported drug of exposure every year since ToxIC was
established. It is distantly followed by ibuprofen (12.3%), as-
pirin (6.7%), and gabapentin (6.5%). Aspirin and
acetylsalicylic acid are listed separately in the registry; when
combined they compose 11.0% of the non-opioid analgesic
class.
Opioids
Table 13 describes the opioid class. Similar to recent years,
heroin was again the most common agent in the class (32.1%)
[2, 3]. The relative contribution of fentanyl increased again
this year, now representing 25.4% of the opioid class
(14.6% in 2019), and again was the second most common
agent.[2] Oxycodone was the third most common agent re-
ported again this year (13.9%) [2]. Other opioid agents
remained fairly stable compared with prior years.





Male to female 17 (26.6)
Female to male 37 (57.8)










> 89 10 (0.1)
Unknown 28 (0.4)
Total 6668 (100)






American Indian/Alaska Native 73 (1.1)











aHispanic ethnicity as indicated exclusive of race
J. Med. Toxicol.
Table 14 describes breakdown of analgesics by race. In
comparing opioid and non-opioid analgesic agents,
acetaminophen was associated with the highest percentage
of encounters across most racial sub-groups. However, among
Table 4 ToxIC registry case
referral sources by inpatient/
outpatient status
N (%)
Emergency department (ED) or inpatient (IP)a
ED 3482 (53.5)
Admitting service 2199 (33.8)
Request from another hospital service (not ED) 412 (6.3)
Outside hospital transfer 370 (5.7)
Poison center 15 (0.2)
Primary care provider or other outpatient treating physician 11 (0.2)
Employer/independent medical evaluation 10 (0.2)
Self-referral 6 (0.1)
ED/IP total 6505 (100)
Outpatient (OP)/clinic/office consultationb
Primary care provider or other OP physician 112 (68.7)
Self-referral 18 (11.0)
Employer/independent medical evaluation 15 (9.2)
Poison center 11 (6.7)
Request from another hospital service (not ED) 3 (1.8)
ED 2 (1.2)
Admitting service 2 (1.2)
Outside hospital transfer 0 (0.0)
OP total 163 (100)
a Percentage based on the total number of cases (N = 6505) seen by a medical toxicologist as consultant (ED or IP)
or as attending (IP)
b Percentage based on the total number of cases (N=163) seen by a medical toxicologist as outpatient, clinic visit,
or office consultation.
Table 5 Reason for medical toxicology encounter
N (%)
Intentional exposure—pharmaceutical 3288 (43.8)
Intentional exposure—non-pharmaceutical 935 (12.5)
Unintentional exposure—pharmaceutical 546 (7.3)
Addiction medicine consultation 532 (7.1)
Withdrawal—ethanol 399 (5.3)
Unintentional exposure—non-pharmaceutical 336 (4.5)
Organ system dysfunction 269 (3.6)
Envenomation—snake 263 (3.5)
Ethanol abuse 242 (3.2)
Withdrawal—opioid 234 (3.1)
Interpretation of toxicology lab data 164 (2.2)
Environmental evaluation 89 (1.2)
Withdrawal—sedative/hypnotic 51 (0.7)







Marine /fish poisoning 5 (0.1)
Total 7501 (100)
Table 6 Detailed reason for encounter—intentional pharmaceutical
exposurea
N (%)a
Reason for intentional pharmaceutical exposure subgroupb
Attempt at self-harm 2408 (73.9)
Misuse/abuse 404 (12.4)
Therapeutic use 240 (7.4)
Unknown 207 (6.4)
Total 3259 (100)
Attempt at self-harm- suicidal intent subclassificationc
Suicidal intent 2105 (87.5)
Suicidal intent unknown 217 (9.0)
No suicidal intent 84 (3.5)
Total 2406 (100)
aNine cases listed more than one reason for encounter due to intentional
pharmaceutical exposure (N = 3251)
b Percentage of total number indicating reason for encounter due to inten-
tional pharmaceutical exposure
c Percentage of number of cases indicating attempt at self-harm
J. Med. Toxicol.
Black and Caucasian patients, opioids were associated with
more encounters compared with other individual non-opioid
analgesics (17.0% Black patients and 12.7% Caucasian
patients).
Antidepressants
Table 15 describes the antidepressant class. SSRIs (39.5%)
and other antidepressants (37.4%) represented the majority
of this class. Sertraline (14.5%) was the most common SSRI
reported and bupropion (21.6%) was the most common other
antidepressant, similar to last year.[2]
Sedative hypnotics
Table 16 presents the sedative hypnotic/muscle relaxant class.
Benzodiazepines (primarily alprazolam (25.8%) and
clonazepam (12.2%)) and muscle relaxants (primarily baclo-
fen (10.2%) and cyclobenzaprine (7.9%)) were the most com-
mon subtypes, similar to recent years. Other sedatives, Z-
drugs, and barbiturates were again less common.
Toxic alcohol and ethanol
Table 17 describes data on ethanol and toxic alcohols. Ethanol
was considered its own agent class, consistent with prior years
and was the fourth most commonly reported agent class (up
from fifth in 2019) [2]. The most commonly reported
nonethanol alcohols and glycols were ethylene glycol
(47.0%) and isopropanol (31.8%). Methanol and miscella-
neous alcohols each made up 10.6% of the class.
Sympathomimetics
Table 18 presents the sympathomimetic class. This year,
methamphetamine (40.3%) overtook cocaine (23.9%) as the
most common agent in this class, followed again by amphet-
amine (10.1%).
Anticholinergic/antihistamine
Table 19 describes the anticholinergic/antihistamine class.
Consistent with recent years, diphenhydramine (58.6%),
followed by hydroxyzine (18.1%), remains the most common-
ly reported agents in this class.
Cardiovascular agents
Table 20 shows data on the cardiovascular class. Consistent
with recent years, sympatholytics (32.5%) remain the most
common subclass of cardiovascular drugs, followed by beta-
blockers (23.5%) and calcium channel blockers (16.5%).
Table 7 Top three primary reasons for encounter by race
N (%)
Native American/Alaska Native 73 (1.1)a
Intentional pharmaceutical 31 (42.3)b
Intentional non-pharmaceutical 11 (15.1)
Envenomation snake 6 (8.2%)
Unintentional pharmaceutical 6 (8.2%)
Asian 155 (2.3)
Intentional pharmaceutical 68 (43.9)
Envenomation snake 27 (17.4)
Unintentional pharmaceutical 13 (8.4)
Black 1007 (15.1)
Intentional pharmaceutical 458 (45.5)
Intentional non-pharmaceutical 144 (14.3)
Unintentional pharmaceutical 119 (11.8)
Caucasian 4174 (62.6)
Intentional pharmaceutical 1987 (47.6)
Intentional non-pharmaceutical 542 (13)
Unintentional pharmaceutical 287 (6.9)
Pacific Islander/Native Hawaiian 7 (0.1)
Intentional pharmaceutical 3 (42.9)
Unintentional non-pharmaceutical 2 (28.6)
Intentional non-pharmaceutical 1 (14.3)
Organ system dysfunction 1 (14.3)
Mixed race 109 (1.6)
Intentional pharmaceutical 60 (55.0)
Intentional non-pharmaceutical 19 (17.4)
Unintentional pharmaceutical 13 (11.9)
a Percentages in bold based on the number of cases in a given race cate-
gory in 2020 relative to the total number of Core Registry cases in 2020
(N = 6668)
b Percentages based on number of cases for a primary encounter type
relative to the number of cases in given race category in 2020
Table 8 Top three primary reasons for encounter by ethnicity
N (%)
Hispanic patients 828 (12.4)a
Intentional pharmaceutical 406 (49.0)b
Intentional non-pharmaceutical 121 (14.6)
Unintentional non-pharmaceutical 63 (7.6)
Non-Hispanic patients 4793 (71.9)
Intentional pharmaceutical 2237 (46.7)
Intentional non-pharmaceutical 614 (12.8)
Unintentional pharmaceutical 390 (8.1)
a Percentages in bold based on the number of cases in a given ethnicity
category in 2020 relative to the total number of Core Registry cases in
2020 (N = 6668)
b Percentages based on number of cases for a primary encounter type
relative to the number of cases in given ethnicity category in 2020
J. Med. Toxicol.
Clonidine (24.0%) and metoprolol (10.0%) were again the
most common sympatholytic and beta-blocker agents,
respectively. Amlodipine (9.8%) remained the most common
calcium channel blocker.
Table 10 Top five primary agent classes by racea
N (%)

























Pacific Islander/Native Hawaiian 7 (0.1)













aCounts include only the primary agent #1 selected for each Core
Registry case
b Percentages in bold based on the number of cases in a given race cate-
gory in 2020 relative to the total number of Core Registry cases in 2020
(N = 6668)
c Percentages based on number of cases for an agent type relative to the
number of cases in given race category in 2020













Envenomation and marine 250 (2.8)
Diabetic medication 129 (1.5)
Lithium 105 (1.2)
Cough and cold products 89 (1.0)
Herbal products/dietary supplements 89 (1.0)
Unknown class 87 (1.0)
Metals 86 (1.0)
Household products 71 (0.8)
Gases/irritants/vapors/dusts 69 (0.8)
Caustic 67 (0.8)
Toxic alcohols 67 (0.8)
Antimicrobials 63 (0.7)
Plants and fungi 49 (0.6)
Hydrocarbon 41 (0.5)
GI 39 (0.4)
Chemotherapeutic and immune 30 (0.3)
Anticoagulant 25 (0.3)
Other pharmaceutical product 25 (0.3)
Endocrine 24 (0.3)
Anesthetic 24 (0.3)





Ingested foreign body 7 (0.1)
Amphetamine-like hallucinogen 7 (0.1)
WMD/riot agent/radiological 5 (0.1)
Anti-parkinsonism drugs 5 (0.1)
Marine toxin 3 (0.0)
Cholinergic 1 (0.0)
Class total 8857 (100)
a Percentages are out of total number of reported agent entries in 2020
from 5987 unique cases; 4262 cases (71.2%) reported single agents
WMD weapons of mass destruction
J. Med. Toxicol.
Antipsychotics
Table 21 details the antipsychotic class. Trends in the antipsy-
chotic class were similar to recent years. The atypicals, led by
quetiapine (41.3%) and olanzapine (13.2%), represent the ma-
jority of cases reported.
Anticonvulsants, mood stabilizers, and lithium
Table 22 presents data on anticonvulsants, mood stabilizers,
and lithium. Consistent with past years, lithium was consid-
ered as its own agent class and made up just over 1% of
reported agents in the Core Registry [2, 3]. Among anticon-
vulsants and mood stabilizers, lamotrigine (29.4%) and
valproic acid (19.4%) were the most commonly reported
agents followed by oxcarbazepine (10.7%) and phenytoin
(9.5%).
Psychoactives
Table 23 presents data on the psychoactive class including the
a m p h e t a m i n e - l i k e h a l l u c i n o g e n
methylenedioxymethamphetamine (Molly). Marijuana was
again the most common agent in this class (25.5%) followed
closely by tetrahydrocannabinol (20.3%). Synthetic cannabi-
noid cases continued to fall again this year (5.6% in 2020 vs
9.4% in 2019 and 12.3% in 2018) [2–4]. When combined, all
non-synthetic cannabinoid product exposures represented
65.7% of the psychoactive class. Molly exposures remained
low, with 7 cases reported.
Envenomations and marine poisonings
Table 24 shows data on envenomations and marine poison-
ings. Snake envenomations represented by Crotalus (35.6%),
Agkistrodon (34.4%), and snake unspecified (17.0) were the
top three exposures reported to this class. Agkistrodon
envenomations showed an increase this year from 16.9% in
Table 11 Top five
primary agent classes by
ethnicitya
N (%)












aCounts include only the primary agent #1
selected for each Core Registry case
b Percentages in bold based on the number
of cases in a given ethnicity category in
2020 relative to the total number of Core
Registry cases in 2020 (N = 6668)
c Percentages based on number of cases for
an agent type relative to the number of







Acetylsalicylic acid 59 (4.3)
Naproxen 41 (3.0)
Pregabalin 14 (1.0)
Salicylic acid 6 (0.4)
Meloxicam 5 (0.4)
Miscellaneousa 11 (0.8)
Class total 1377 (100)



















Class total 1128 (100)




2019, nearly approaching that of Crotalus envenomations.
Again in 2020, Loxosceles exposures were the fourth most
common exposure in this class (5.1%) [2–4].
Diabetic agents
Table 25 presents the diabetic medication agent class.
Metformin was the most common agent at 39.4% of the agent
class, followed by insulin (22.5%) and glipizide (21.7%).
Metals
Table 26 presents the metal class. Lithium is its own agent class
and is reported with the anticonvulsants and mood stabilizers.
Trends were similar to recent years with lead (37.6%) and iron
(28.2%) composing the majority of reported cases [2–4]. Mercury
and arsenic were reported each in 6 (7.1%) cases.
Herbal products and dietary supplements
Table 27 details herbal products and dietary supplements.
Caffeine (38.2%) and melatonin again made up the majority
of this class [2, 3]. Infrequently reported miscellaneous agents
made up 38.2% of the agent class.
Household agents
Table 28 describes household agents reported to the Core
Registry. Cleaning solutions and disinfectants (28.2%),
Table 14 Comparison of opioid and non-opioid analgesic frequencies
by racea
N (%)






















Pacific Islander/Native Hawaiian 7 (0.1)
Acetaminophen 1 (14.2)
Opioid 1 (14.2)





aCounts include only cases for which an opioid or non-opioid analgesic
was selected as primary agent #1
b Percentages in bold based on the number of cases in a given race cate-
gory in 2020 relative to the total number of Core Registry cases in 2020
(N = 6668)
c Percentages based on number of cases for an agent type relative to the
number of cases in given race category in 2020
Table 15 Antidepressants
N (%)












Antidepressant unspecified 3 (0.3)









Monoamine oxidase inhibitor (MAOIs) 2 (0.2)
Phenelzine 2 (0.2)
Class total 923 (100)
a Includes vortioxetine, tianeptine, sibutramine
b Includes imipramine, clomipramine, desipramine, noxiptiline
c Includes desvenlafaxine, levomilnacipran
J. Med. Toxicol.
laundry detergent pods (19.7%), and sodium hypochlorite < 6%
(12.7%) were the most commonly reported agents in this class.
Gases, irritants, vapors, and dusts
Table 29 presents data for the gases, irritants, vapors, and
dusts class. Carbon monoxide again represented the large ma-
jority of this class (63.8%).
Cough and cold preparations
Table 30 details data on cough and cold preparations reported
to the Core Registry. Dextromethorphan was again the most
commonly reported agent, making up 77.5% of the class.
Caustics
Table 31 presents the caustic agent class. Sodium hydroxide
was the most common agent reported in this class (17.9%)
followed by sodium hypochlorite concentration unknown
(14.9%).
Antimicrobials
Table 32 presents data on antimicrobial agents. Antibiotics
were the most common subclass (57.2%), with amoxicillin
representing 15.9% and miscellaneous antibiotics
representing 41.3% of this class. Antivirals and other antimi-
crobials were less common.


















Other sedatives 35 (5.9)
Buspirone 16 (2.7)
Sed-hypnotic/muscle relaxant unspecified 10 (1.7)
Miscellaneousb 9 (1.5)









Class total 598 (100)
a Includes chlordiazepoxide and bromazepam
b Includes propofol, phenibut (beta-phenyl-gamma-aminobutyric acid),
meprobamate, flumazenil, etizolam, and acamprosate
c Includes butabarbital, pentobarbital, and barbituate unspecified
Table 17 Ethanol and
toxic alcohols N (%)
Ethanola 743 (100)
Nonethanol alcohols and glycols




Class total 66 (100)
aEthanol is considered a separate agent
class
b Includes diethylene glycol, denatured al-
cohol, ethylene glycol monohexyl ether,
glycolic acid, toxic alcohol unspecified,
and triethylene glycol mono butyl ether








MDMA (Methylenedioxy-N-methamphetamine,Ecstasy) 12 (2.1)




Class total 566 (100)
a Includes phentermine, atomoxetine, mixed amphetamine salts, clenbu-
terol, cathinone, norepinephrine, pseudoephedrine, and epinephrine
J. Med. Toxicol.
Plants and fungi
Table S1 describes plant and fungi exposures reported to the
Core Registry. In 2020 mold was again the most common
single exposure (26.5%) followed by Mitragyna speciosa
(kratom) (16.3%). Infrequent miscellaneous agents, however,
made up the majority of this class (57.1%).
Hydrocarbons
Table S2 presents the hydrocarbon agent class. The largest
single contributor to the class was toluene (14.6%), however,
infrequent miscellaneous agents represented the majority
(73.2%) of the class.
Gastrointestinal agents
Table S3 presents gastrointestinal agents. Ondansetron
(25.6%), omeprazole (12.8%), famotidine (12.8%) and
pantoprazole (10.3%) were the most commonly reported
agents.
Insecticides, herbicides, rodenticides, and fungicides
Table S4 presents the pesticide (insecticide, herbicide, roden-
ticide and fungicide) class. There were 13 herbicides reported
(41.9%), with glyphosate being themost common. There were
11 (35.5%) insecticides and 9 (29.0%) rodenticides. No fun-
gicides were reported.
Chemotherapeutic and immunological agents
Table S5 describes chemotherapeutic and immunological agents.
Methotrexate (23.3%), hydroxychloroquine (13.3%), and colchi-
cine (13.3%) were the three most commonly reported agents.
Anticoagulants
Table S6 details anticoagulant class exposures. Warfarin















Anticholinergic unspecified 5 (1.0)
Cetirizine 5 (1.0)
Miscellaneousa 20 (3.9)
Class total 514 (100)




Table 20 Cardiovascular agents by type
N (%)





























Cardiac Glycosides 21 (4.0)
Digoxin 20 (3.8)
Digitoxin 1 (0.2)





Class total 520 (100)
a Includes labetalol, nadolol, and levobunolol
b Includes minoxidil, doxazosin, isobutyl nitrite, sacubitril, nitroprusside,
isosorbide, and antihypertensive unspecified
c Includes valsartan, olmesartan, enalapril, and benazepril
d Includes torsemide and chlorthalidone
e Includes sotalol, flecainide, dofetilide, ranolazine, and dronedarone
f Includes atorvastatin, rosuvastatin, pravastatin, and fenofibrate
J. Med. Toxicol.
Anesthetics
Table S7 describes the anesthetic class exposures reported in
2020. Lidocaine and benzonatate (each 29.2%) were the most
commonly reported agents.
Other pharmaceuticals
Table S8 presents the other pharmaceutical products agent
class. The majority of the class (72.0%) was made up of
infrequently reported miscellaneous agents. Sumatriptan was
the most commonly reported single agent (16.0%).
Endocrine
Table S9 describes the 24 endocrine agents reported.
















Class total 409 (100)


















Class total 252 (100)
aLithium is considered a separate agent
class
b Includes anticonvulsant unspecified,
clobazam, eslicarbazepine, felbamate,
lacosamide, tiagabine, and zonisamide
Table 23 Psychoactives
N (%)
Molly - Amphetamine-like hallucinogena 7 (100)
Marijuana 78 (25.5)
Tetrahydrocannabinol 62 (20.3)
Cannabinoid nonsynthetic 28 (9.2)
Delta-9-tetrahydrocannabinol 21 (6.9)
LSDb 19 (6.2)
Cannabinoid synthetic 17 (5.6)




Hallucinogenic amphetamines 6 (2.0)
Miscellaneousc 17 (5.6)
Class total 306 (100)
aAmphetamine-like hallucinogens are considered a separate agent class
b LSD lysergic acid diethylamide
c Includes methylenedioxymethamphetamine, psychoactive unspecified,




Crotalus (Rattlesnake) 90 (35.6)
Agkistrodon (Copperhead, Cottonmouth/Water moccasin) 87 (34.4)
Snake unspecified 43 (17.0)
Loxosceles (Recluse spiders) 13 (5.1)
Miscellaneousa 20 (7.9)
Class total 253 (100)
a Includes Centruroides (var Scorpion incl Bark), Latrodectus (Widow
spiders), Palytoxin, Vipera palaestinae, spider unspecified, Pyrrharctia
isabella (isabella tiger moth), Scolopendra (var Centipede incl Giant
Desert, Giant Sonoran, Texas red headed), envenomation unspecified,
scorpion unspecified, Cigueterra poisoning, animal bite unspecified,
and Hymenoptera (Bees, Wasps, Ants)
J. Med. Toxicol.
Other non-pharmaceuticals
Table S10 describes the other non-pharmaceutical class.
Water (13.0%), silicone (13.0%), and lactic acid (13.0%) were
the three most common agents reported.
Pulmonary agents
Table S11 describes reported pulmonary agents. Montelukast
was the most common agent reported (66.7%).
Foreign bodies
Table S12 details the foreign object ingestions reported to the
Core Registry. Batteries were the most common objects
(42.9%).
Anti-Parkinsonism agents
Table S13 presents the anti-parkinsonism agent class, contain-
ing 5 entries. Reported agents included pramipexole,
ropinirole, levodopa/carbidopa, and rasagiline.
Weapons of mass destruction
Botulinum toxin (5 cases) was the only agent reported in the
class of weapons of mass destruction, described in Table S14.
Cholinergics
Table S15 describes the single cholinergic/parasympathetic
agent reported, cholinergic/parasympathetic unspecified.
Clinical signs and symptoms
The categories of clinical signs and symptoms describe a di-
verse range of abnormal clinical findings. Predefined criteria
must be met for each category in order for a sign or symptom
to be reported as present. For example, tachycardia is defined
as a heart rate greater than 140 beats per minute. Additionally,








Class total 129 (100)
a Includes dulaglutide, empagliflozin,
gliclazide, glimepiride, linagliptin,









Class Total 85 (100)
a Includes cobalt, chromium, copper, cad-
mium, cilver, platinum, manganese, mag-








Class total 89 (100)
a Includes aloin (aloe vera extract or outer
leaves), biotin, black cohosh, dietary sup-
plement unspecified, eucalyptus oil, guara-
na, herbal (dietary) multibotanical, L-car-
nitine, methylxanthine, multiple vitamin,
potassium, prenatal vitamin, saw palmetto,
sodium chloride, vitamin B complex (un-
defined), vitamin B3 (niacin), vitamin B6
(pyridoxine), vitamin C (ascorbic acid), vi-
tamin D, vitamin E (tocopherol), yerba
mate green tea extract, yohimbine, and
zinc
Table 28 Household products
N (%)
Cleaning solutions and disinfectants 20 (28.2)
Laundry detergent pod 14 (19.7)
Sodium hypochlorite ≤ 6% 9 (12.7)
Hand sanitizer unspecified 6 (8.5)
Miscellaneousa 22 (31.0)
Class total 71 (100)
a Includes ammonia ≤ 10%, aromatic or essential oils (carrier/solvent base
unspecified), diaper rash ointment, dishwasher detergent, dishwasher de-
tergent pod, drain cleaner (irritant), hair product, household product un-
specified, mequinol (4-methoxyphenol), moisturizer/lotion, oven cleaner,
soaps and detergents, windshield washer fluid
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group or across groups. For example, a single case entry may
havemultiple vital sign abnormalities or may have both a vital
sign abnormality and a neurologic abnormality. The percent-
ages for these categories and their individual signs and symp-
toms are calculated relative to the total number of Core
Registry cases (N = 6668). It is therefore possible for the total
to be more than 100%.
Toxidromes
Table 33 reports the 1844 toxidromes reported to the Core
Registry in 2020. Consistent with recent years, the sedative-
hypnotic toxidrome was the most common (8.3%). This year
the opioid toxidrome (3.7%) overtook serotonin syndrome
(3.0%) as the third most common toxidrome reported.
Major vital sign abnormalities
Table 34 presents the 1738 vital sign abnormalities reported to
the Core Registry in 2020. Trends were nearly identical to
recent years. Tachycardia (11.2%), hypotension (6.2%), and
bradycardia (3.4%) were the most common vital sign abnor-
malities reported.
Clinical signs and symptoms—neurologic
Table 35 describes the 5111 neurologic clinical signs and
symptoms reported to the Core Registry in 2020. Coma/
CNS depression (27.6%), agitation (16.4%), hyperreflexia/
myoclonus/clonus/tremor (10.6%) and delirium/toxic psycho-
sis (10.0%) were the most commonly reported signs, similar to
last year [2].
Clinical signs and symptoms—cardiovascular and pulmonary
Table 36 presents the 553 cardiovascular and 745 pulmonary
clinical signs reported to the Core Registry in 2020. QTc pro-
longation (5.1%) and respiratory depression (7.8%) remained
the most common signs in their respective categories again





Carbon monoxide 44 (63.8)
Chlorine 7 (10.1)
Miscellaneousa 18 (26.1)
Class Total 69 (100)
a Includes cyandide, bromide, chloramine,
vaping NOS, acetonitrile, copper cyanide,
cyclohexyl nitrate, duster (canned air),
gases/vapors/irritants/dusts unspecified,
nitrogen oxides, petroleum vapors, smoke,
volatile organic compounds (VOCs)
unspecified




Cough and cold unspecified 7 (7.9)
Camphor 1 (1.1)
Class total 89 (100)
Table 31 Caustics
N (%)
Sodium hydroxide 12 (17.9)
Sodium hypochlorite (concentration unknown) 10 (14.9)
Cleaning agent 8 (11.9)
Caustic unspecified 6 (9.0)
Sodium hypochlorite > 6% 6 (9.0)
Miscellaneousa 39 (41.5)
Class total 67 (100)
a Includes acetic acid, ammonium chloride nonpharmaceutical, ammoni-
um nitrate, boric acid (hydroborate), cement, drain cleaner, formalde-
hyde, hydrochloric acid, hydrogen peroxide > 10%, hydroxy undecanoic
acid, lithium hydroxide, peroxyacetic acid (peracetic acid), phosphoric









Other Antimicrobials 9 (14.3)
Miscellaneousc 9 (14.3)
Class total 62 (100)
a Includes ciprofloxacin, clavulanic acid, clindamycin, dapsone, doxycy-
cline, levofloxacin, linezolid, metronidazole, minocycline, penicillin, pi-
peracillin, rifampin, rifaximin, tazobactam, vancomycin.
b Includes acyclovir, amantadine, bictegravir, darunavir, emtricitabine,
ritonavir, valacyclovir.
c Includes antimicrobial unspecified, benzalkonium chloride,
itraconazole, piperazine citrate, quinine.
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Clinical signs—other organ systems
Table 37 presents the other organ system clinical signs which
include metabolic, renal and musculoskeletal, hematological,
gastrointestinal and hepatic, and dermatological. Metabolic
abnormalities were again the most frequently reported
(10.4%), and among these an elevated anion gap (4.0%) and
metabolic acidosis (4.0%) were the most common [2, 3].
Renal and musculoskeletal abnormalities were the next most
commonly reported (7.4%), with acute kidney injury (4.3%)
being the most common sign in this subgroup. Hepatotoxicity
was the most common gastrointestinal and hepatic abnormal-
ity (2.8%). Coagulopathy was the most commonly reported
hematological abnormality (1.6%). Dermatological
abnormalities were less frequently reported (3.4%), with rash
being the most common (1.6%).
Fatalities
There were 81 fatalities in 2020, comprising 1.2% of Core
Registry cases. Single-agent exposures were implicated in
34 cases (Table 38), 26 cases involved multiple agents
(Table 39), and in 21 cases it was unknown if there was a
toxicologic exposure (Table 40).
There were 12 fatalities (14.8%) involving opioids, an de-
crease from 2019 and 2018 in which opioids were reported in
19.8% and 34.0% of Core Registry deaths, respectively [2, 3].
Fentanyl was reported in 2 deaths (2.5%) this year compared
with 5.5% in 2019 and 9.4% in 2018 [2, 3]; 3 deaths (3.7%)







Serotonin syndrome 197 (3.0)
Alcoholic ketoacidosis 89 (1.3)
Sympatholytic 39 (0.6)
Washout syndrome 16 (0.2)
Cannabinoid hyperemesis 8 (0.1)
NMSb 7 (0.1)
Overlap syndromes 6 (0.1)
Cholinergic 5 (0.1)
Anticonvulsant hypersensitivity 2 (< 0.1)
Class total 1844 (27.7)
a Percentage based on the number cases reporting specific toxidrome
relative to total number of Registry cases in 2020 (N=6668)
b NMS neuroleptic malignant syndrome
Table 34 Major vital sign
abnormalities N (%)
a
Tachycardia (HR > 140) 744 (11.2)
Hypotension (systolic BP < 80 mmHg) 411 (6.2)
Bradycardia (HR < 50) 229 (3.4)
Bradypnea (RR< 10) 166 (2.5)
Hypertension (systolic BP > 200 mmHg and/or diastolic BP > 120 mmHg)
Hyperthermia (temp > 105° F)
147 (2.2)
41 (0.6)
Class total 1738 (26.1)
HR heart rate, BP blood pressure, RR respiratory rate
a Percentage based on the number of cases relative to the total number of Registry cases in 2020 (N = 6668). There
were 1407 unique cases (21.1% of all Registry cases) reporting at least one major vital sign abnormality. Cases
may be associated with more than one major vital sign abnormality
Table 35 Clinical signs and symptoms—neurologic
N (%)a
Coma/CNS depression 1842 (27.6)
Agitation 1094 (16.4)
Hyperflexia/Myoclonus/Clonus/Tremor 704 (10.6)






Peripheral Neuropathy (objective) 17 (0.3)
Class total 5111 (76.6%)
a Percentages are based on the total number of cases reported to the
Registry in 2020 (N = 6668); 3590 Registry cases (53.8%) reported at
least one neurologic clinical effect. Cases may have reported multiple
effects
J. Med. Toxicol.
Acetaminophen was the most common agent involved in
both single and multiple agent fatalities; there were 11
fatalities (13.6%) involving acetaminophen, 5 as a sin-
gle agent. A single death was reported after laundry pod
exposure in a > 89-year-old that sustained a corrosive
gastrointestinal injury. A single agent pancrelipase death
in a 7-year-old after medication administering error due
to the wrong medication (either wrong route or dilution
technique) was reported. A single agent lactulose death
in a 2-year-old also due to a medication dosing error
after receiving 75 g chronically was reported with respi-
r a to ry depress ion , CNS depress ion , se i zu re s ,
hypernatremia, and hyperglycemia. A single agent para-
quat death was reported in a 60-year-old who presented
with hypotension, tachycardia, QRS and QTc prolonga-
tion, and gastrointestinal bleeding. He was treated with
activated charcoal, NAC, steroids, vitamin C, and mag-
nesium sulfate. A multi-agent death involving intention-
al verapamil exposure, with a subsequent lipid emulsion
medication dosing error given intranasally, was reported
in a 65-year-old. In addition to treatment for the verap-
amil exposure, she was treated with enhanced elimina-
tion and ECMO specifically related to the medication
error.
In 2020 there were 13 pediatric (age 0–18 years) deaths due
to a known toxicologic exposure (16.1%), compared with
20.0% in 2019 [2]. The age range was 13 months to 18 years.
Nine were single agent exposures and 4 involved multiple
agents. No pediatric exposures involved acetaminophen in
2020, whereas 35.7% of pediatric exposures in 2019 involved
acetaminophen. Three deaths involved opioids in pediatric
patients. One single agent methamphetamine death was re-
ported in a 13-month old.
There were 46 fatality cases in which life support was
withdrawn, representing 0.7% of Core Registry cases. It was
unknown whether life support was withdrawn in an additional
7 cases. Brain death was declared in 19 cases.
Table 36 Clinical signs—cardiovascular and pulmonary
N (%)a
Cardiovascular
Prolonged QTc (≥ 500 ms) 339 (5.1)
Prolonged QRS (≥ 120 ms) 85 (1.3)
Myocardial injury or infarction 70 (1.0)
Ventricular dysrhythmia 45 (0.7)
AV Block (> 1st degree) 14 (0.2)
Class total 553 (8.3)
Pulmonary
Respiratory depression 517 (7.8)
Aspiration pneumonitis 107 (1.6)
Acute lung injury/ARDSb 92 (1.4)
Asthma/Reactive airway disease 29 (0.4)
Class Total 745 (11.2)
a Percentage based on number cases reporting signs or symptoms relative
to total number of Registry cases in 2020 (N = 6668). There were 1147
unique cases (17.02% of all Registry cases) that reported at least one
cardiac or pulmonary clinical effect. Cases may be associated with more
than one sign or symptom
b ARDS acute respiratory distress syndrome
Table 37 Clinical signs—other organ systems
N (%)a
Metabolic
Elevated anion gap (> 20) 269 (4.0)
Metabolic acidosis (pH < 7.2) 268 (4.0)
Hypoglycemia (glucose < 50 mg/dL) 105 (1.6)
Elevated osmole gap (> 20) 50 (0.7)
Total 692 (10.4)b
Renal/musculoskeletal
Acute kidney injury (creatinine > 2.0 mg/dL) 289 (4.3)
Rhabdomyolysis (CPK > 1000 IU/L) 207 (3.1)
Total 496 (7.4)b
Gastrointestinal/Hepatic
Hepatotoxicity (AST ≥ 1000 IU/L) 187 (2.8)
Hepatotoxicity (ALT 100–1000 IU/L) 60 (0.9)
Hepatotoxicity (ALT ≥ 1000 IU/L) 56 (0.8)
Gastrointestinal bleeding 42 (0.6)
Pancreatitis 34 (0.5)
Corrosive injury 28 (0.4)
Intestinal ischemia 5 (0.1)
Total 412 (6.2)b
Hematological
Coagulopathy (PT > 15 s) 110 (1.6)
Leukocytosis (WBC > 20 K/μL) 91 (1.4)
Thrombocytopenia (platelets < 100 K/μL) 83 (1.2)
Hemolysis (Hgb < 10 g/dL) 63 (0.9)









AST aspartate aminotransferase, PT prothrombin time,WBC white blood
cells, Hgb hemoglobin, CPK creatine phosphokinase
a Percentage equals the number of cases reporting specific clinical signs
compared to the total number of Registry cases in 2020 (N = 6668)
bTotal reflects cases reporting at least one sign in the category. Casesmay














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 41 presents the common drugs associated with adverse
drug reactions reported to the Core Registry in 2020. One
hundred seventy-seven ADRs (2.7% of cases) were reported
in 2020. Lithium was again the most common drug reported
(10.2%), similar to recent years.
Treatment
Antidotal therapy
Table 42 describes the 2777 antidotes reported to the Core
Registry in 2020. Similar to last year, N-acetylcysteine
(28.3%), followed by naloxone/nalmefene (15.5%), and thia-
mine (15.0%) were the three most common antidotes reported
[2]. In 2020, 31.0% of Core Registry cases received at least
one antidote compared with 26.3% in 2019 [2].
Antivenom therapy
Table 43 presents data on antivenom therapies reported to the
Core Registry. Crotalidae polyvalent immune Fab (ovine)
again made up the majority (65.7%) of antivenom adminis-
tered, however its relative contribution continued to decline
(73.9% in 2019 from 94.2% in 2018) in this year.[2, 3]
Crotalidae immune Fab2 (equine) antivenom, introduced in
2019 (19.9%) increased to 31.0% of cases of administered
antivenom in 2020.
Pharmacologic supportive care
Table 44 describes the 3260 pharmacologic supportive care
treatments reported in 2020. Benzodiazepines were again the
most commonly reported agents (47.1%), followed by opioids
(12.8%) and vasopressors (8.1%).
Non-pharmacologic supportive care
Table 45 presents non-pharmacologic supportive care treat-
ments reported to the Core Registry in 2020. IV fluid resusci-
tation (76.1%) and intubation/ventilatory management
(19.3%), remain the most common treatments in this category.
Chelation therapy administered
Table 46 presents data on chelation therapy administered.
There were 22 chelation agents reported in 2020.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 47 describes the 246 decontamination interventions ad-
ministered. Activated charcoal again represented the signifi-
cant majority (91.5%) in this class.
Enhanced elimination interventions administered
Table 48 presents the enhanced elimination interventions re-
ported. Hemodialysis for toxin removal (28.4%), continuous
renal replacement therapy (25.3%), followed by urinary alka-
linization (22.1%) and hemodialysis for other reasons (17.9%)
topped the reported interventions in this class.
Discussion
This report describes the 11th year of data collected for the
Toxicology Investigators’ Consortium Registry. Core Registry
case numbers decreased slightly this year; however in light of
the COVID-19 pandemic, that drop was not unexpected. Despite
this, the Core Registry continued to grow, adding six new sites this
year and increasing quality control measures.
Although the Core Registry is not strictly population based,
it represents a wide geographic distribution of cases evaluated
by medical toxicologists. These data can be used in conjunc-
tion with data from other registries including the National
Poison Data System to provide a more detailed picture of
poisoning trends, novel exposures, and their public health
implications.
This 11th annual report finds overall trends in agent clas-
ses, agents, demographics, types of encounters, clinical signs
and symptoms, and treatments to be largely unchanged from
recent years. Notable findings or trends in the Core Registry
are discussed below.
In 2019, the opioid class jumped to the second most com-
mon agent class reported to the Core Registry; this trend
Table 41 Most common drugs associated with adverse drug reactions
N (%)
Lithium 18 (10.2)






Class total 177 (100)
a Includes gabapentin, morphine, citalopram, propofol, ondansetron, ris-
peridone, benztropine, fluoxetine, haloperidol, guanfacine, metoprolol,
phenytoin, linezolid, methadone, naloxone, olanzapine, diphenhydra-
mine, duloxetine, lamotrigine, paliperidone, scopolamine, verapamil,
aripiprazole, sertraline, carbamazepine, bupropion, amlodipine, amitrip-
tyline, etanercept, diltiazem, amiodarone, dextromethorphan, ethinyl es-
tradiol, ferric carboxymaltose (iron dextran), flumazenil, alprazolam, acy-
clovir, ethanol, arsenic, corticosteroid, bupivacaine, clozapine,
dexmedetomidine, dapsone, cyproheptadine, crotalus (rattlesnake),
Crotalidae Immune Fab2 (Equine, Anavip), carvedilol, chlordiazepoxide,
clomipramine, clonidine, cocaine, atenolol, succinylcholine, lidocaine,
pregabalin, prilocaine, rasburicase, rifampin, ropivacaine, sed-hypnotic/
muscle relaxant unspecified, piperacillin, sotalol, physostigmine, suma-
triptan, tazobactam, temazepam, tramadol, triamcinolone, unknown
agent, valacyclovir, vecuronium, sitagliptin, LSD, glyburide,
hydromorphone, insulin, isoflurane,itraconazole, acetaminophen,
lisdexamfetamine, pramipexole, lisinopril, glipizide, methotrexate, meth-
ylphenidate, metoclopramide, nadolol, nicardipine, nifedipine, nortripty-
line, phenazopyridine, and ziconotide















Insulin-Euglycemic therapy 27 (1.0)
Carnitine 22 (0.8)
Vitamin K 18 (0.6)
Lipid resuscitation therapy 17 (0.6)
Pyridoxine 17 (0.6)
Methylene blue 16 (0.6)
Fab for digoxin 10 (0.4)
Hydroxocobalamin 8 (0.3)
Dantrolene 5 (0.2)
Botulinum antitoxin 4 (0.1)
Anticoagulation reversal 2 (0.1)
Bromocriptine 2 (0.1)
Thiosulfate 2 (0.1)
2-PAM 1 (< 0.1)
Ethanol 1 (< 0.1)
Silimarin 1 (< 0.1)
Class total 2777 (100)
a Percentages are based on the total number of antidotes administered (N
= 2777); 2066 (31.0%) cases received at least one antidote. Cases may
have involved the use of multiple antidotes
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continued again this year. Despite that increase, relative per-
centage of reported opioid-related deaths has fallen over the
last several years (14.8% vs 19.8% vs 34.0% for 2020, 2019,
and 2018, respectively).[2, 3]
Relative contribution of fentanyl to the opioid class exposures
continues to increase (25.4% vs 14.6% vs 10.1% for 2020, 2019,
and 2018, respectively) [2, 3] and remains the second most com-
mon opioid reported in 2020. Oral opioids such as oxycodone,
methadone, buprenorphine, tramadol, and hydrocodone remained
relatively stable this year.
In 2020 ethanol became the 4th most common agent class
reported, overtaking the sedative hypnotic/muscle relaxant class.
Marijuana and THC/CBD-related products continues to
represent the majority of the psychoactive class (65.7%) and
relative contribution of synthetic cannabinoid cases continued
to fall.
With regards to envenomations, 2020 saw new trends in-
cluding an increase in relative Agkistrodon cases (34.4% in
2020 vs 16.9% in 2019). Two of the six new sites added to the
Core Registry in 2020 commonly report Agkistrodon cases,
possibly driving this year’s trend. In addition, the use of
Crotalidae immune Fab2 (equine) antivenom continued to in-
crease this year (31.0% in 2020 vs 19.9% 2019) [2].
Telemedicine encounters
Table 49 presents data on the 144 telemedicine encounters
reported in 2020. This was the first year such data was col-
lected in the Core Registry, prompted by the COVID-19 pan-
demic and national rise of telemedicine as a mode of patient
care. Most evaluations were for patients physically located in
the emergency department at the time of the encounter (n = 74;
Table 43 Antivenom therapy
N (%)a
Crotalidae polyvalent immune fab (ovine) 142 (65.7)
Crotalidae immune fab2 (equine) 67 (31.0)
Other snake antivenom 4 (1.9)
Scorpion antivenom 2 (0.9)
Spider antivenom 1 (0.5)
Class total 216 (100)
a Percentages are out of the total number of antivenom treatments admin-
istered (N = 216)







Glucose > 5% 113 (3.5)








Class total 3260 (100)
a Percentages based on the total number of pharmacologic interventions
(N = 3260); 2243 Registry cases (33.6%) received at least one pharma-
cologic intervention. Cases may have involved the use of multiple
interventions
Table 45 Supportive care—non-pharmacologic
N (%)a
IV fluid resuscitation 2446 (76.1)
Intubation/ventilatory management 621 (19.3)
CPR 56 (1.7)
Transfusion 20 (0.6)




Hyperbaric oxygen 6 (0.2)
Transplant 2 (0.1)
Cardiopulmonary bypass 1 (< 0.1)
Class total 3213 (100)
a Percentages are based on the total number of treatments administered (N
= 3213); 2619 Registry cases (39.3%) received at least one form of
nonpharmacologic treatment. Cases may have involved the use of multi-









Class Total 22 (100)
a Percentages are out of the total number of
chelation treatments administered (N=22);
20 Registry cases (0.3%) received at least
one form of chelation treatment. DMSA
d ime rc ap t osucc in i c ac id , EDTA
ethylenediamine-tetraacetic acid
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51.4%). Sixty-five (45.1%) occurred via telemedicine instead
of in person because of concerns for infection, while 14
(9.7%) were due to a hospital policy. COVID-19 status was
only known in 19 (13.2%) patients; 3 were positive and 16
were negative. Half of the telemedicine consults consisted of
chart reviews (50.7%).
Only seven evaluations (4.9%) were primarily addiction
medicine evaluations, five of which were for initiation of opi-
oid agonist therapy. No telemedicine evaluations were for
adverse drug reactions or medication errors. Toxicology ther-
apeutic intervention was administered to 94 (65.3%) patients,
but only 75 (52.1%) of telemedicine evaluations were billed.
COVID
A new set of COVID-19 specific questions were incorporated
into the ToxIC Core Registry on August 1, 2020. After this
implementation, a total of 3119 toxicological exposure cases
were reported in 2020. Fifty-one cases (1.6%) were
COVID-19 positive, 1397 (44.8%) were COVID-19 negative,
and 1671 (53.6%) were unknown. Regarding the COVID-19
cases, males represented 54.9%; there were no transgender
COVID-19-positive patients. Age and gender breakdown of
COVID-19 cases are described in Table 50. The toxic expo-
sures in COVID-19 patients were largely unrelated to
COVID-19; only 5 (9.8%) exposures were related to
COVID-19 treatment or prophylaxis. Of the patients present-
ing with a toxic exposure, the four most common reasons for
encounter include intentional pharmaceutical (50.9%), inten-
tional non-pharmaceutical (15.7%) and unintentional pharma-




Activated charcoal 225 (91.5)
Whole bowel irrigation 14 (5.7)
Irrigation 5 (2.0)
Gastric lavage 2 (0.8)
Class total 246 (100)
a Percentages based on the total number of
decontamination interventions (N = 246);
240 Registry cases (3.6%) received at least
one decontamination intervention. Cases
may have involved the use of multiple
interventions
Table 48 Enhanced elimination
N (%)a
Hemodialysis (toxin removal) 54 (28.4)
Continuous renal replacement therapy 48 (25.3)
Urinary alkalinization 42 (22.1)
Hemodialysis (other indication) 34 (17.9)
Multiple-dose activation charcoal 11 (5.8)
Exchange transfusion 1 (0.5)
Class total 190 (100)
a Percentages are based on the total number of treatments administered (N
= 190); 168 Registry cases (2.5%) received at least one form of enhanced
elimination




Admitting service 50 (34.7)
Poison center 1 (0.7)
Outside hospital transfer 3 (2.1)
Nature of consultation
Consult from ED or inpatient service 126 (87.5)
Admitting toxicology service 5 (3.5)
Outpatient clinic 13 (9.0)
Nature of telemedicine consult
Chart review 73 (50.7)
Over the phone 16 (11.1)
Over video/Internet 54 (37.5)
Unknown 1 (0.7)
Reason for encounter
Attempt at self-harm 38 (26.4)
ETOHb withdrawal 3 (2.1)
Opioid withdrawal 1 (0.7)
Occupational evaluation 5 (3.5)
Interpretation of laboratory data 3 (2.1)
Organ system dysfunction 5 (3.5)
Envenomation 9 (6.3)
Total telemedicine encounters 144 (100)
a ED emergency department
b ETOH ethanol
Table 50 Encounters for toxic exposures in COVID-19 positive pa-
tients by age and gender
Female N (%)a Male N (%)a Total N (%)a
Age 2–6 2 (3.9) 1 (2.0) 3 (5.9)
Age 7–12 1 (2.0) 1 (2.0) 2 (3.9)
Age 13–18 7 (13.7) 7 (13.7) 14 (27.4)
Age 19–65 10 (19.6) 18 (35.3) 28 (54.9)
Age 66–89 3 (5.9) 1 (2.0) 4 (7.8)
Class total 23 (45.1) 28 (54.9) 51 (100)
a Percent based on total number of cases (N = 51)
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Agent exposures related to COVID-19 treatment or prophylax-
is are described in Table 51. There were no children in this group.
Only one case was related to a self-harm attempt. The remaining
cases were intentional (3/4) or unintentional (1/4) supratherapeutic
dosing.Acetaminophenwas themost common agent (4 of 5 cases;
80.0%); all acetaminophen cases required NAC treatment and 3/4
developed a transaminitis.
Limitations
The ToxIC Core Registry is a unique prospective database of
cases in which bedside or telemedicine consultation is per-
formed by medical toxicologists, enabling an informed rela-
tionship between exposures and clinical outcomes.
Limitations, however, do exist for the Core Registry. One of
these is a bias towards inclusion of more severe case presen-
tations, as cases are only included if they undergo subspecialty
consultation. Cases for which a medical toxicology consulta-
tion was not requested are not reported and may represent a
group with less severe illness. Therefore, the Core Registry
likely represents a different population from other data sources
such as Poison Control Centers. Regional differences may
lead to a disproportionate number of specific cases reported
based on variations in drug use, abuse, and other toxic expo-
sures. The ToxIC Core Registry includes sites from multiple,
diverse locations, but the entire country is not uniformly rep-
resented. Larger academic medical centers with greater
amounts of medica l tox ico logy facul ty may be
over-represented in the database.
At the level of the individual sites, there may be a reporting
bias towards more complicated or interesting cases. Although
the express intent of the Core Registry, as defined in written
agreements with all sites, is to obtain a consecutive sample of
all cases at a given site, individual cases may be missed. Data
regarding substances of exposure or species of envenomation
relies heavily on patient self-report and may be misclassified;
this limitation is likely of most significance with regard to
illicit drug exposure and patient hesitancy to disclose detailed
information. Lastly, efforts are made to continually improve
the quality of data collected. While member sites are
instructed to complete all applicable data fields, there are still
a number of cases and data fields with incomplete informa-
tion. This remains an issue for collection of race and ethnicity,
for example. Efforts continue to support quality data collec-
tion and follow up on missing data where applicable.
Conclusions
The ToxIC project continues to grow and evolve, including
the Core Registry and additional surveillance projects. The
Core Registry remains unique amongst databases in that it
represents prospective data collected from cases evaluated
by medical toxicologist specialists. Although this feature
limits extrapolation to the population as a whole, it increases
the potential for high-quality data and for increased correlation
between exposure cases and clinical findings. Continued qual-
ity improvement and surveillance efforts remain areas of focus
for the Core Registry and of ToxIC as a whole.
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